Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018

information fournie par Boursorama •12/11/2018 à 07:30

Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018


• Primary end-point reached: safety established following single dose and multiple doses administration of TG1050 in chronic hepatitis B patients under antiviral (NUC) therapy
• TG1050 triggers T cell-based immune responses, specific of all 3 encoded HBV antigens, confirming the mechanism of action of the product
• New preclinical data clearly support further investigation of TG1050 in combination with antivirals or immunomodulators

.../...